This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Background. The EUropean REgistration of Cancer CAre (EURECCA) consortium aims to investigate differences in treatment and to improve cancer care through Europe. The purpose of this study was to compare neo-and adjuvant chemotherapy (ACT) and outcome after tumor resection for pancreatic adenocarcinoma stage I and II in the EUR-ECCA Pancreas consortium. Methods. The eight, collaborating national, regional, and single-center partners shared their anonymized dataset. Patients diagnosed in 2012-2013 who underwent tumor resection for pancreatic adenocarcinoma stage I and II were investigated with respect to treatment and survival and compared using uni-and multivariable logistic and Cox regression analyses. All comparisons were performed separately per registry type: national, regional, and singlecenter registries. Results. In total, 2052 patients were included. Stage II was present in the majority of patients. The use of neo-ACT was limited in most registries (range 2.8-15.5%) and was only different between Belgium and The Netherlands after adjustment for potential confounders. The use of ACT was different between the registries (range 40.5-70.0%), even after adjustment for potential confounders. Ninety-day mortality was also different between the registries (range 0.9-13.6%). In multivariable analyses for overall survival, differences were observed between the national and regional registries. Furthermore, patients in ascending age groups and patients with stage II showed a significant worse overall survival. Conclusions. This study provides a clear insight in clinical practice in the EURECCA Pancreas consortium. The differences observed in (neo-)ACT and outcome give us the chance to further investigate the best practices and improve outcome of pancreatic adenocarcinoma. Pancreatic cancer (PC) is one of the few types of cancer with increasing incidence and mortality rates. 1 In 2017, the number of annual deaths in the European Union due to PC will exceed the number of death due to breast cancer. 2 Resection is the only chance for prolonged survival; unfortunately only 15-20% of PC patients are eligible for resection due to advanced or metastatic disease at diagnosis. 3 Tumor/node/metastases (TNM) stage I and II PC

recalcification, activity of NO-synthase and myeloperoxidase (MPO) in pancreas. Results: The concentration of creatinine in serum is increase at 86.86%. It was noticed that the level of creatinine significantly directly correlated with the concentration of MPO and activity of iNOS in the pancreas, amylase in serum blood, and reverse with the concentration of H2S in serum. Renal failure in rats was accompanied by a hypercoagulation, determined by probable direct correlation between the levels of creatinine and fibrinogen, inverse relationship between creatinine concentrations and plasma recalcification time. Enoxaparin ameliorates morphology of the pancreas and kidney. The enoxaparin normalized serum creatinine, fibrinogen, amylase, MPO, H2S, decreased activity of iNOS. Conclusion: Enoxaparin in experimental AP reduces morphological signs of damage in the pancreas and kidneys, the intensity nitrosative stress and inflammation, normalizes hemostasis.

accuracy was calculated by measuring distances of anatomical landmarks between 3D model and in-situ liver (mm RMS). Results: Ten patients were recruited to the study. Ease of use, mental integration and accuracy were rated positively (8 each). Length of setup time was rated negatively (2). Objectively measured accuracy was 137AE39. A consensus was reached to integrate depth fogging, outlining and plane clipping as enhanced visualisation features into SmartLiver (video). Conclusion:The findings of this study demonstrate that SmartLiver is easy to use and capable of creating an AR environment that integrates well into the surgical workflow. Enhanced visualisation methods may improve the interpretation of AR data. An automatic registration method is needed to improve accuracy and setup time.

No abstract